And that's why Merck could credibly become the next big weight-loss stock. Before you rush to go buy shares of Merck, ...

The weight-loss biotech Viking Therapeutics ( VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...

Merck has entered into a global licensing agreement with Chinese biopharmaceutical company Hansoh Pharma to develop an oral small molecule GLP-1 receptor agonist, HS-10535.

According to data compiled by S&P Global Market Intelligence, the biotech's share price fell by just over 10% over the period ...

This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, ...

The latest health news highlights the FDA's approval of Ionis Pharma's drug for genetic disorder FCS, CVS's legal troubles ...

While a formidable competitor, Merck remains far behind and a small ... it may differentiate VK2735 as a best-in-class drug for weight loss. An oral drug would be compelling, bypassing injections ...

Pfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated ...

Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its weight-loss drug. On Wednesday, Merck & Co Inc (NYSE:MRK) and Hansoh ...

Novo Nordisk A/S (CPH: NOVO-B) is being punished this morning after posting a disappointing update related to CagriSema. The ...

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity ...